Key Points
- Gilead insider Johanna Mercier sold 3,000 shares at an average price of $156.22, generating $468,660. The transaction was made under a pre-arranged Rule 10b5-1 plan, and she retains 113,684 shares.
- Gilead reported quarterly revenue of $7.80 billion, exceeding estimates, while revenue increased 10.6% year over year. The company also declared a quarterly dividend of $0.82, equivalent to a 2.1% annualized yield.
- Analysts maintain a generally positive view, with a consensus rating of “Moderate Buy” and an average price target of $159.33; shares recently traded near their 52-week high.
Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) insider Johanna Mercier sold 3,000 shares of the business's stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total transaction of $468,660.00. Following the completion of the transaction, the insider owned 113,684 shares of the company's stock, valued at $17,759,714.48. The trade was a 2.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Johanna Mercier also recently made the following trade(s):
- On Tuesday, September 15th, Johanna Mercier sold 3,000 shares of Gilead Sciences stock. The stock was sold at an average price of $144.22, for a total transaction of $432,660.00.
- On Monday, August 17th, Johanna Mercier sold 28,000 shares of Gilead Sciences stock. The stock was sold at an average price of $137.64, for a total transaction of $3,853,920.00.
Gilead Sciences Price Performance
NASDAQ:GILD traded down $1.18 during mid-day trading on Friday, reaching $156.19. The stock had a trading volume of 7,770,853 shares, compared to its average volume of 5,976,056. The stock has a 50-day simple moving average of $147.19 and a two-hundred day simple moving average of $137.29. The stock has a market capitalization of $193.67 billion, a PE ratio of -58.50 and a beta of 0.31. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. Gilead Sciences, Inc. has a 12 month low of $114.02 and a 12 month high of $160.51.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, beating the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. During the same period in the previous year, the business earned $2.01 earnings per share. The company's revenue was up 10.6% on a year-over-year basis. On average, equities analysts anticipate that Gilead Sciences, Inc. will post -0.47 earnings per share for the current year.
Gilead Sciences Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th were paid a $0.82 dividend. The ex-dividend date was Tuesday, September 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.1%. Gilead Sciences's dividend payout ratio (DPR) is presently -122.85%.
Wall Street Analysts Forecast Growth
Several analysts recently weighed in on the company. Bank of America restated a "buy" rating and set a $164.00 price objective on shares of Gilead Sciences in a research report on Monday, October 12th. Weiss Ratings raised Gilead Sciences from a "hold (c-)" rating to a "hold (c)" rating in a research note on Monday, September 14th. HSBC boosted their target price on Gilead Sciences from $155.00 to $175.00 and gave the stock a "buy" rating in a research note on Thursday, September 10th. Royal Bank Of Canada increased their target price on shares of Gilead Sciences from $123.00 to $126.00 and gave the stock a "sector perform" rating in a report on Thursday, October 8th. Finally, Wall Street Zen upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating in a research note on Saturday, September 19th. Twenty-three research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $159.33.
Get Our Latest Analysis on Gilead Sciences
Trending Headlines about Gilead Sciences
Here are the key news stories impacting Gilead Sciences this week:
- Positive Sentiment: Vir oncology collaboration expands Gilead’s pipeline. Gilead and Vir Biotechnology agreed to develop three novel cancer therapies, including next-generation T-cell engagers. The deal could provide Vir with up to approximately $1.74 billion in additional milestone payments, giving Gilead access to potential long-term oncology growth while diversifying its pipeline. Gilead and Vir forge $1.9bn pact to develop next-gen T-cell engagers
- Positive Sentiment: Investors are rotating toward defensive healthcare stocks. As investors reduce exposure to technology and chip stocks, major pharmaceutical companies—including Gilead—have traded near record highs. This rotation may be supporting demand for GILD because of the sector’s defensive characteristics and potential earnings support. Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets
- Neutral Sentiment: Recent momentum has increased investor attention. GILD gained 2.57% in the prior session and closed at $157.48, while shares remain close to their 52-week high. Market commentary notes heightened investor interest, although analysts have expressed mixed views on the company’s prospects. Gilead Sciences rises higher than market: Key facts
- Negative Sentiment: Two senior executives reported planned stock sales. CFO Andrew Dickinson and insider Johanna Mercier each sold 3,000 shares at an average price of $156.22. Both transactions were executed under pre-arranged Rule 10b5-1 plans, limiting their significance as a bearish signal; each executive continues to hold a substantial position. Gilead CFO Form 4 filing
Institutional Investors Weigh In On Gilead Sciences
Hedge funds have recently added to or reduced their stakes in the business. Strategic Investment Solutions Inc. IL bought a new stake in Gilead Sciences during the 4th quarter worth approximately $25,000. Persistent Asset Partners Ltd bought a new position in shares of Gilead Sciences during the second quarter valued at $25,000. Kimelman & Baird LLC bought a new position in shares of Gilead Sciences during the second quarter valued at $25,000. Wealth Preservation Advisors LLC raised its stake in shares of Gilead Sciences by 60.0% during the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 81 shares during the last quarter. Finally, Wiser Advisor Group LLC acquired a new position in shares of Gilead Sciences during the second quarter worth $30,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.
About Gilead Sciences
(
Get Free Report)
Gilead Sciences, Inc (NASDAQ: GILD) is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. Its research and commercial activities focus primarily on virology, including HIV, hepatitis B and hepatitis C, as well as oncology, inflammation and other areas of significant unmet medical need.
Gilead's portfolio includes HIV treatments such as Biktarvy, Descovy, Genvoya and Sunlenca; hepatitis therapies including Epclusa, Harvoni and Vemlidy; and Veklury (remdesivir), an antiviral used to treat COVID-19 in certain patients.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
